FOMX - Foamix Pharmaceuticals Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.4900
+0.0300 (+1.22%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close2.4600
Open2.4900
Bid2.4000 x 800
Ask3.4400 x 800
Day's Range2.4050 - 2.5100
52 Week Range2.4000 - 7.6000
Volume182,708
Avg. Volume379,655
Market Cap135.52M
Beta (3Y Monthly)2.14
PE Ratio (TTM)N/A
EPS (TTM)-1.3240
Earnings DateAug 6, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.50
  • Thomson Reuters StreetEvents9 days ago

    Edited Transcript of FOMX earnings conference call or presentation 8-May-19 12:30pm GMT

    Q1 2019 Foamix Pharmaceuticals Ltd Earnings Call

  • SmarterAnalyst11 days ago

    Foamix (FOMX): A Beaten-Down Biotech Stock That Looks Like a Bargain Now

    Get ready, bargain shoppers. Foamix (FOMX) has plummeted 27% since the beginning of the year and it looks like the stock received more lashes than it deserved -- at least, according to Wall Street analysts.2019 is poised to be a transformative year for Foamix. The company's acne treatment FMX101 is currently pending regulatory review in the U.S, and a PDUFA date of October 20, 2019 has been set. Furthermore, Foamix plans to submit a New Drug Application (NDA) for FMX103 during mid-2019, following positive long-term safety data in papulopustular rosacea patients. Now, let's take a closer look at what analysts are expecting ahead of October's FDA decision.FMX101's Approval Chances and ForecastsCredit Suisse analyst Vamil Divan sees a high likelihood of regulatory approval for FMX101, applying a 90% probability of success (POS). The analyst rates FOMX stock an Outperform with a $9.00 price target, which implies nearly 250% upside from current levels. With an FDA approval in hand (100% POS), Divan says his price target will be boosted to $11.00. According to the analyst, "an increase in the sample size (1,507 patients in this trial vs. ~500 each in the two prior trials) and improved site selection and training helped drive statistically significant [clinical] results," which put the company on track to win FDA approval.Similarly, H.C Wainright analyst Ram Selvaraju estimates the probability of regulatory approval at 85%, and assigns a $12.00 price target for the stock. If the price target is reached within 12 months, that would provide a 12-month return of nearly 360%. Selvaraju opined, "We believe that the current valuation situation presents an attractive entry point for value-focused investors, given the fact that Foamix currently trades about 2x book value [...] Our risk-adjusted net present value (rNPV) of FMX101 is $400M, which factors in an 85% probability of regulatory approval [...] We have employed a sum-of-the-parts valuation approach that yields a total projected firm value of $696M, which translates into a price objective of $12.00 assuming ~59M fully-diluted shares outstanding as of end-2019."Commercial Opportunity Selvaraju believes investors seem to be discounting both FMX101 and FMX103 from a commercial standpoint, but "this is unwarranted." Why? "These agents are based on well-known, validated and effective compounds in their respective target indications and have generated statistically significant efficacy data in large, robustlypowered pivotal studies. We also draw investors' attention to the large size and underserved nature of the target markets—namely, acne and rosacea—and the willingness of patients and physicians alike to try new formulations when they are introduced. Furthermore, we point to the user-friendly and well-tolerated nature of the Foamix formulations, which utilize the company's proprietary foam-based delivery technology to enhance efficacy while minimizing off-target systemic side effects," Selvaraju answers.Cowen analyst Ken Cacciatore has recently spoken with 3 dermatology KOLs; they all agreed that "the clinical data were as good or better than they would have expected," and, according to the analyst, one has indicated that "it looked "more impressive" than Aczone (which peaked at over $200MM+ before genericization)." Cacciatore believes that given the wide use of oral minocycline, clinicians are eager to have this option with potential similar efficacy yet without the the systemic side effects, and therefore, the marketing of FMX-101 should be a very easy story to tell. The analyst says "FMX-101 should be able to easily surpass the peak prescription levels of Aczone (via our consultants' feedback)," and "this would place FMX-101 to achieve at least $250MM in revenue." Furthermore, the analyst believes FMX-101 could ultimately reach his target of $350MM given what he believes will be "improved efficacy/outcomes." Cacciatore argues that "even undifferentiated dermatology assets are selling at 3x peak revenue. Using just FMX-101 alone – and the low-end ($250MM) of what we believe will be the ultimate product size – would yield a value of $750MM, or $13-15 per share."Bottom lineFoamix has seen its shares struggle mightily this year, but analysts continue to believe that this beaten-down biotech stock is a sure-fire winner. Analysts are confident that lead asset, FMX101, has substantial potential in treating acne, with an upcoming October 20, 2019 PDUFA date as a key potential positive catalyst for FOMX shares.This latest pullback has arguably skewed the risk-to-reward ratio for the better -- perhaps making FOMX an attractive buy for risk-tolerant investors. More recent articles from Smarter Analyst: * Love or Hate Aurora Cannabis (ACB) Stock, That’s Where the Money Is * Micron's (MU) Tech Roadmap Highlights Flattening Cost Curve, Says Analyst; Reiterates Neutral on the Stock * Time to Cash Out on Cannabis Stock Canopy Growth (CGC) * GW Pharmaceuticals (GWPH) Stock Could Run Much Higher Over Time

  • Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX): The Best Of Both Worlds
    Simply Wall St.17 days ago

    Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX): The Best Of Both Worlds

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Foamix Pharmaceuticals (FOMX) Q1 2019 Earnings Call Transcript
    Motley Fool17 days ago

    Foamix Pharmaceuticals (FOMX) Q1 2019 Earnings Call Transcript

    FOMX earnings call for the period ending March 31, 2019.

  • Foamix (FOMX) Reports Q1 Loss, Misses Revenue Estimates
    Zacks19 days ago

    Foamix (FOMX) Reports Q1 Loss, Misses Revenue Estimates

    Foamix (FOMX) delivered earnings and revenue surprises of -16.67% and -67.58%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press19 days ago

    Foamix: 1Q Earnings Snapshot

    The Rehovot, Israel-based company said it had a loss of 28 cents per share. The acne treatment developer posted revenue of $308,000 in the period. In the final minutes of trading on Tuesday, the company's ...

  • GlobeNewswire19 days ago

    Foamix Reports First Quarter 2019 Financial Results and Provides Corporate Update

    FDA Accepts NDA for FMX101, Sets October 20, 2019 as PDUFA Action Date Conference Call Scheduled for Wednesday May 8th at 8:30am Eastern Time REHOVOT, Israel and BRIDGEWATER,.

  • GlobeNewswire20 days ago

    Foamix Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019

    REHOVOT, Israel, and BRIDGEWATER, N.J., May 06, 2019 -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), clinical stage specialty pharmaceutical company focused on.

  • Will Foamix (FOMX) Report Negative Earnings Next Week? What You Should Know
    Zacks26 days ago

    Will Foamix (FOMX) Report Negative Earnings Next Week? What You Should Know

    Foamix (FOMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire27 days ago

    Foamix to Present Late Breaking Data at the 77th Annual Meeting of the Society for Investigative Dermatology

    Foamix Pharmaceuticals Ltd. (FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced it will present two late-breaking posters relating to its topical product candidate FMX101, a 4% minocycline foam being developed for the treatment of moderate-to-severe acne, at the 77th Annual Meeting of the Society for Investigative Dermatology to be held May 8-11, 2019, in Chicago, Illinois. Foamix  previously announced that the U.S. Food & Drug Administration (FDA) has accepted the filing of a New Drug Application for FMX101 for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients nine years of age and older and the FDA has set an action date of October 20, 2019 under the Prescription Drug User Fee Act (PDUFA).

  • GlobeNewswirelast month

    Foamix Pharmaceuticals First Quarter 2019 Financial Results Conference Call & Webcast Scheduled for May 8

    REHOVOT, Israel and BRIDGEWATER, N.J., April 24, 2019 -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on.

  • This Small-Cap Biotech Stock Could Triple in 2019
    GuruFocus.comlast month

    This Small-Cap Biotech Stock Could Triple in 2019

    Investing in biotech stocks can provide true binary opportunities. If the drug succeeds, small-cap biotech stocks easily become multi-baggers. Warning! GuruFocus has detected 2 Warning Signs with FOMX.

  • What Kind Of Share Price Volatility Should You Expect For Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)?
    Simply Wall St.2 months ago

    What Kind Of Share Price Volatility Should You Expect For Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Anyone researching Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) might want to consider the historical volatility of the share pr...

  • GlobeNewswire2 months ago

    Foamix Announces Settlement of Litigation with Perrigo Relating to Finacea Foam

    Foamix Pharmaceuticals Ltd. (FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that, together with LEO Pharma, it has settled the Hatch-Waxman litigation with Perrigo, relating to Finacea® Foam. "Together with LEO Pharma, we are pleased to have settled the outstanding litigation with Perrigo," said David Domzalski, Chief Executive Officer of Foamix. Foamix is the owner of patents that have been licensed to LEO Pharma to market Finacea® Foam, a topical prescription medicine used to treat the inflammatory papules and pustules of mild to moderate rosacea.

  • GlobeNewswire3 months ago

    Foamix Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2019

    REHOVOT, Israel and BRIDGEWATER, N.J., March 08, 2019 -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of FOMX earnings conference call or presentation 1-Mar-19 1:30pm GMT

    Q4 2018 Foamix Pharmaceuticals Ltd Earnings Call

  • GlobeNewswire3 months ago

    Foamix Announces FDA Acceptance of New Drug Application for FMX101 Minocycline Foam for the Treatment of Moderate-to-Severe Acne

    Foamix Pharmaceuticals Ltd. (FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that the U.S. Food & Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for FMX101.  Foamix is seeking approval of FMX101 for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients nine years of age and older.  The FDA has set October 20th, 2019 as the Prescription Drug User Fee Act (PDUFA) action date.

  • GlobeNewswire3 months ago

    Foamix Pharmaceuticals to Present at the Cowen & Company 39th Annual Health Care Conference

    REHOVOT, Israel and BRIDGEWATER, N.J., March 06, 2019 -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on.

  • GlobeNewswire3 months ago

    Foamix Reports Fiscal Year 2018 Financial Results and Provides Corporate Update

    REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 28, 2019 -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix Pharmaceuticals” or the “Company”), a clinical stage specialty.

  • How Many Insiders Bought Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Shares?
    Simply Wall St.3 months ago

    How Many Insiders Bought Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insidersRead More...

  • GlobeNewswire3 months ago

    Foamix Announces Positive Results from Phase 3 Open-Label Safety Study Evaluating FMX103 Topical Minocycline Foam for Treatment up to One Year

    Foamix Pharmaceuticals Ltd. (FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced positive safety and efficacy data for its Phase 3 open-label safety study (FX2016-13), evaluating FMX103 in moderate-to-severe papulopustular rosacea for a treatment period of up to 1 year. The open-label safety study enrolled a total of 505 patients, all of whom had completed 12 weeks of FMX103 or vehicle treatment in the preceding double-blind studies (FX2016-11 or FX2016-12).

  • GlobeNewswire3 months ago

    Foamix -- with Late-Stage Candidates in Acne and Rosacea -- to Participate at American Academy of Dermatology Annual Meeting

    Foamix Pharmaceuticals Ltd. (FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that it will participate in the American Academy of Dermatology (AAD) Annual Meeting to take place March 1 – 5, 2019 at the Walter E. Washington Convention Center, in Washington D.C. Clinical data on the Company’s late stage clinical development candidates, FMX101 for moderate to severe acne, and FMX103 for papulopustular rosacea, are expected to be covered in oral presentations by leading clinical dermatologists during the meeting.

  • GlobeNewswire3 months ago

    Foamix Pharmaceuticals Fourth Quarter Financial Results Conference Call & Webcast Scheduled for March 1

    REHOVOT, Israel, and BRIDGEWATER, N.J., Feb. 14, 2019 -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on.

  • GlobeNewswire4 months ago

    Foamix Announces Appointment of Sharon Barbari to Board of Directors

    Foamix Pharmaceuticals Ltd. (FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the appointment of Sharon Barbari to its Board of Directors. “I am honored to join Foamix’s Board of Directors and I look forward to helping guide the company through its anticipated upcoming pivotal milestones for its lead candidates FMX101 and FMX103,” said Ms. Barbari. Ms. Barbari joins Foamix’s Board with over 40 years of pharmaceutical and biotechnology experience.